Genialis

For industry leaders, biomarkers aren’t just ☒ checkboxes in a clinical program They’re 𝗺𝗮𝗸𝗲-𝗼𝗿-𝗯𝗿𝗲𝗮𝗸 𝗳𝗮𝗰𝘁𝗼𝗿𝘀 in drug development and patient care Here’s how we help tip the scales: 🧬 With Debiopharm, a leader in DNA Damage Repair (DDR) therapeutics, we're developing a predictive biomarker for WEE1-targeted therapy 💊 For a biopharma partner developing an innovative RAS inhibitor, we delivered a proof-of-concept biomarker algorithm tuned to the drug and indication – all in under six weeks 🎗️ With Pancreatic Cancer Action Network, we identified probabilities of response to KRAS inhibitors across multiple patient genotypes to guide personalized treatment And that’s just the start See how we’re working with industry leaders to develop biomarkers that deliver real impact: https://lnkd.in/dX4auFtX

➡️ Do you want your pivotal oncology clinical trial to fail? ➡️ Do you want to understand better how and why your drug works? Or why some patients develop resistance? ➡️ Do you want to know which patients will respond to your drug and in whom, a combination drug strategy may work better? ➡️ Do you want your oncology drug to be first-in-class AND best-in-class? Read my article below with an epic example that shows why a Biomarker-Driven Strategy is a No-Brainer. Genialis

Great biopharma leaders don’t roll the dice with drug development, so why should you? 🎲 Precision in treatment selection isn’t a luxury; it’s the key to smarter drug development and better patient outcomes A recent study in 𝘑𝘊𝘖 𝘖𝘯𝘤𝘰𝘭𝘰𝘨𝘺 𝘗𝘳𝘢𝘤𝘵𝘪𝘤𝘦 highlights the impact of 𝗰𝗼𝗺𝗽𝗿𝗲𝗵𝗲𝗻𝘀𝗶𝘃𝗲 𝗴𝗲𝗻𝗼𝗺𝗶𝗰 𝗽𝗿𝗼𝗳𝗶𝗹𝗶𝗻𝗴 (CGP) in cancer treatment ➡️ 𝟲𝟳% of tumors tested with CGP had actionable alterations - compared to 𝟯𝟯% with small-panel testing ➡️ Patients with advanced solid tumors who received 𝗖𝗚𝗣-𝗴𝘂𝗶𝗱𝗲𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀 had a median overall survival of 𝟮𝟱 𝗺𝗼𝗻𝘁𝗵𝘀, versus 𝟭𝟳 𝗺𝗼𝗻𝘁𝗵𝘀 for those treated with chemotherapy alone The takeaway? 𝗖𝗚𝗣 𝗲𝘅𝗽𝗮𝗻𝗱𝘀 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗼𝗽𝘁𝗶𝗼𝗻𝘀 𝗮𝗻𝗱 𝗿𝗲𝗶𝗻𝗳𝗼𝗿𝗰𝗲𝘀 𝘁𝗵𝗲 𝗴𝗿𝗼𝘄𝗶𝗻𝗴 𝗻𝗲𝗲𝗱 𝗳𝗼𝗿 𝗽𝗿𝗲𝗰𝗶𝘀𝗲 𝗯𝗶𝗼𝗺𝗮𝗿𝗸𝗲𝗿𝘀 At Genialis, we’re committed to advancing RNA biomarkers that support every aspect of clinical development - for every oncology target, drug, and patient Read the study: https://lnkd.in/gmGT2fkw What do you think the biggest challenge in integrating CGP into routine clinical care?

RNA-seq normalization shouldn’t be a guessing game 🤔 Choosing the right method can be challenging, and your bioinformatics would benefit from better tools to streamline the process That’s why we built 𝗥𝗡𝗔𝗻𝗼𝗿𝗺; an open-source Python toolkit designed to simplify RNA-seq normalization and integrate seamlessly with machine learning workflows 🔹 Open-source, built for the community 🔹 Scikit-learn compatible Check it out on GitHub: https://lnkd.in/dPyBWrTQ Not sure where to start? Our tutorial covers common normalization methods and how to apply them using RNAnorm: https://lnkd.in/dJefp8-6 Better tools - better science 🤝

"𝗧𝗵𝗮𝘁 is one of the bigger ethical ponds we're willing to swim in." ⬇️ Rafael Rosengarten explains why diverse, real-world patient data is essential for training AI models Listen to his candid conversation with Kristen Revell now: https://lnkd.in/dK-zbWqZ

“The things that have enriched me the most are things that I didn't know 𝘐 𝘥𝘪𝘥𝘯'𝘵 𝘬𝘯𝘰𝘸. In any new job, there are things you know, things you know you don’t know, and then there are things where you go, wow, I had no clue I would be learning X, Y, and Z. And I think that has always been the most enriching part of any new role I've taken on.” In the latest episode of the Talking Precision Medicine podcast, we are thrilled to welcome Joydeep Goswami President & CEO of LGC Find the full episode here: 🎙️ https://lnkd.in/ddusZSBB Hosted by Genialis' CEO, Rafael Rosengarten, they dive into: 🔹 The biotech industry's cautious optimism and how funding, regulation, and global trends will shape the next phase 🔹 The expanding role of AI in drug discovery, clinical trials, and patient care, supporting but not replacing human expertise 🔹 What Joydeep learned about the art of listening when he moved to Japan and had to adapt to a new business culture

The field of DNA Damage Response (DDR) is evolving rapidly, and precise patient selection is crucial for optimizing clinical outcomes That’s why Genialis is proud to announce we’re extending our partnership with Debiopharm to develop a predictive RNA biomarker for WEE1-targeted therapy—advancing the way we identify the right patients for the right treatments Why pursue an RNA biomarker strategy? 💡  🚀  Faster, Higher-Yield Trials – By pinpointing responders, reduce trial sizes, costs, and time to market 📈 Reduced Risk & Increased ROI – Reliable identification of responders ensures successful clinical development and meaningful drug differentiation 🌍 A Head Start on Emerging Standards – Our AI-powered Supermodel is built on a globally diverse collection of RNA-seq samples, analyzing over 50 billion data points to hone in on true molecular signals DDR therapies, including WEE1, offer significant opportunities to improve outcomes—but success hinges on accurate biomarker strategies As the DDR landscape expands (think ATR, ATM, and WEE1), so does the window for first-mover advantage. If your R&D team isn’t leveraging new biomarker technology now, those who do may leave you behind Come talk to us and get a glimpse of what’s possible. Sami Takriti and Daniel Pointing will be attending the 8th Annual DDR Inhibitors Summit in Boston (Jan 28-30), and we'll be presenting an abstract about our collaboration with Debiopharm at AACR 2025 in April. Learn more in our latest press release: https://lnkd.in/dZ-Zar6g

"If you can hire for values and diversity of experience, you're going to create an amazing team and an amazing workforce." In Part 4 of The Biotech Startups Podcast conversation with Genialis CEO & Co-Founder Rafael Rosengarten, we explore the importance of building diverse and value-driven teams in the biotech industry. In this episode, we cover: – The power of hiring for values and diverse experiences in creating exceptional teams – Navigating the challenges of building a startup in the competitive biotech landscape – The role of AI and machine learning in advancing precision medicine – Balancing scientific innovation with business acumen in the biotech sector – Strategies for effective leadership and fostering a culture of innovation This insightful discussion offers valuable perspectives on team building and innovation in the ever-evolving world of biotechnology. Head over to Apple Podcasts or Spotify for this episode and more stories only a biotech exec can tell! #biotechnology #lifesciences #podcast

Continuing with our 2025 #IndustryInsights feature, we’re excited to showcase the thought leadership, insights, and predictions from AAIH members at the forefront of AI in healthcare. Today, we’re thrilled to highlight Genialis, one of our valued members who is driving innovation and progress, determined to close the data gap in cancer care! Genialis has partnered with Tempus to leverage their multimodal dataset, advancing the validation of Genialis™ Supermodel and driving the development of new RNA-based algorithms across various cancer types. Read more about how Genialis strives to show the clinical value and wide-ranging potential of biomarkers in drug development and patient care. https://lnkd.in/ge-8hfAn  

"I think this is why being okay with not having a plan and being comfortable just chasing your passion is a pretty good survival skill. It's a pretty good approach to these things. If you have faith and some amount of security, things will work out." In Part 3 of The Biotech Startups Podcast, we explore the power of embracing uncertainty with Rafael Rosengarten, CEO & Co-Founder of Genialis, as he shares his journey from marine biology to pioneering AI-driven precision oncology. Below are some highlights from our conversation: – The serendipitous path from studying slime molds at Baylor College of Medicine to groundbreaking machine learning applications in biomedicine 🧫 – How a chance collaboration with Slovenian AI experts in 2011 positioned him at the forefront of the biotech-AI revolution 🧬 💻 – The founding story of Genialis and the courage to pivot from a SaaS model to becoming a leader in predictive biomarkers 🔮 – The importance of solving "hard but boring problems" that nobody else had tackled in clinical genomics 🥱💡 – Building a resilient team that stayed together through major transitions and salary cuts to emerge stronger 🌱💪 Rafael brilliantly illustrates how embracing uncertainty while following your passion can lead to breakthrough innovations in biotechnology. An absolute Masterclass. Apple Podcasts & Spotify links in the comments below 👇 #biotechnology #lifesciences #podcast